Please assess the completion status of the following clinical trial:

Trial Title: Hypersensitivity to Opening of ATP-Sensitive Potassium Channels in Post-Traumatic Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 65 years of age upon entry into screening~* History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)~* ≥ 4 monthly headache days on average across the 3 months prior to screening~* Provision of informed consent prior to initiation of any study-specific activities/procedures.~Exclusion Criteria:~* \> 1 mild traumatic injury to the head~* History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)~* History of moderate or severe injury to the head~* History of whiplash injury~* History of craniotomy~* History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion~* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior~* Female subjects of childbearing potential with a positive pregnancy test during any study visit~* Cardiovascular disease of any kind, including cerebrovascular diseases~* Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day~* Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg)~* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion~* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start~* Baseline headache intensity of \>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)~* Baseline headache with migraine-like features or self-reported baseline headache that mimics the subjects' usual headache with migraine-like features

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Levcromakalim (Type: EXPERIMENTAL): A time- and volume-controlled infusion pump is used to administer levcromakalim by intravenous infusion over 20 minutes.
- Placebo (isotonic saline) (Type: PLACEBO_COMPARATOR): A time- and volume-controlled infusion pump is used to administer placebo (isotonic saline) by intravenous infusion over 20 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).